Document is current
Any future updates will be listed below
-
Authors
Manzouri, Bita https://orcid.org/0000-0002-4589-0831
Ahmad, Sajjad
Harper, Sophie
Kolli, Sai
Lockington, David https://orcid.org/0000-0001-7984-0958
O’Gallagher, Michael
Dua, Harminder https://orcid.org/0000-0002-4683-6917
-
Funding
Funding for this research was provided by:
Santen Ltd
- License Information
-
More Information
Article History
Received: 29 September 2025
Revised: 11 February 2026
Accepted: 23 February 2026
First Online: 14 March 2026
Competing interests
: BM has received lecturer fees, honoraria for mentoring and educational delivery, and served as chair and advisory board member for ciclosporin-related meetings sponsored by Santen. SA has received honoraria and an educational grant from Santen. SH is an assessor and examiner for the College of Optometrists and a senior lecturer for the Independent Prescribing (IP) programme at Cardiff University. She has received honoraria from Santen and Bausch & Lomb. SK has received speaker fees from Santen, Thea and Visufarma. DL has received consultancy and speaker honoraria from Santen. MO has received consultancy and speaker fees from Santen UK, as well as speaker fees and travel expenses from Thea Pharmaceuticals, Scope Pharmaceuticals, and Alcon UK. HD is a consultant to Arctic Vision, NuVision Biotherapies, Santen, Seagen, and Thea. He holds a patent for Omnigen and owns shares in GlaxoSmithKline and NuVision Biotherapies. He is the Editor-in-Chief of Eye .
